Cell line · CVCL_0064
Papers125
1 to 20 of 125
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Development of Trivalent BRD4 PROTACs: Advancing Targeted Protein Degradation Strategies. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IL10RB-AS1 promotes pro-caspase-1-dependent pyroptosis via regulating the oligomerization and nucleation of CARD8 C-terminal domain to suppress acute myeloid leukemia. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacologically Targeting DHODH-Dependent Pyrimidine Metabolism with HSA-Conjugated BRQ Suppresses Leukemogenesis. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Localized heme sensing through a ternary molecular glue. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic Switching of Apoptosis-Modulating Bim Heterodimers in Response to BH3 Mimetics in Xenograft Models of Hematologic Malignancies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Biomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia. | Adv Healthc Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DualPG-DTA: A Large Language Model-Powered Graph Neural Network Framework for Enhanced Drug-Target Affinity Prediction and Discovery of Novel CDK9 Inhibitors Exhibiting In Vivo Anti-Leukemia Activity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrated scFv identification and CAR T cell generation for AML targeting in vivo. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0064/papers